Skip to main content

Cognitive enhancers – drugs given to Alzheimer's patients to improve concentration, memory, alertness and moods – do not improve mental function in people with mild cognitive impairment, researchers say.

Mild cognitive impairment, or MCI, is marked by memory lapses and problems with language, thinking and decision-making that go beyond what is expected with normal aging, but are not as pronounced as the changes that would signal the onset of dementia.

However, up to 17 per cent of MCI patients do go on in time to develop a dementia such as Alzheimer's disease.

Story continues below advertisement

Doctors sometimes prescribe cognitive enhancers to people with mild cognitive impairment in the hope of helping improve their memory and day-to-day functioning.

In Canada, physicians need special authorization to give the medications to people with MCI.

"More and more patients and their families are requesting these medications," said Andrea Tricco, a scientist at St. Michael's Hospital in Toronto, who led a study looking at the drugs' effects on MCI patients.

"It is a form of medication creep in that a lot of people seem to be going to their doctors and asking for them."

In a review of international studies that tested cognitive enhancers in people diagnosed with mild cognitive impairment, the Toronto researchers found the drugs had no benefit over the long term and had numerous side-effects.

The study, published on Monday in the Canadian Medical Association Journal, assessed the results of eight clinical trials that involved almost 5,000 MCI patients, aged 66 to 73.

Patients were given one of four cognitive enhancers – donepezil, rivastigmine, galantamine and memantine – or a dummy pill.

Story continues below advertisement

"We found that they weren't helpful and that actually they also caused harm," Tricco said.

"So they caused significantly more headaches, nausea, vomiting and diarrhea, compared to patients who received placebo."

"Patients and their families should consider this information when requesting these medications," the authors write.

"Similarly, health-care decision makers may not wish to approve the use of these medications for mild cognitive impairment, because these drugs might not be effective and are likely associated with harm."

Dr. Serge Gauthier, director of the Alzheimer's disease research unit at McGill University's Centre for Studies in Aging, said the authors' conclusions are in line with recommendations of the 2012 Canadian Consensus Conference on the Diagnosis and Treatment of Dementia.

"We reiterated that this is the wrong stage [of dementia] to treat," Gauthier said, noting that there are no medications at this point to slow the process of mild cognitive impairment.

Story continues below advertisement

"Frankly, the kind of drug you need is often an antidepressant more than an Alzheimer's-specific drug because [patients] realize there's a change in their cognitive ability," he said Monday from Montreal.

"They worry it's going to get worse, and if you need a pill, it's often an antidepressant or something for anxiety."

However, eventual dementia isn't a given for all people with mild cognitive impairment; some never get worse, and a few eventually get better, depending on the underlying cause.

Doctors now are able to predict with greater accuracy which MCI patients will go on to develop a full-fledged dementia, using brain scans and tests looking for specific proteins in spinal fluid, Gauthier said.

That has changed how doctors classify patients within the spectrum of mild cognitive impairment and how they should be treated.

Report an error
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter